BQ Blue's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BloombergQuint's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
KRChoksey Research Report
For Q4 FY22, Tatva Chintan Pharma Chem Ltd. reported revenue of Rs 985.3 million as against Rs 1086.7 million in Q4 FY21 amid subdued demand in structure directing agents led by continued semiconductor shortage during the quarter.
Ebitda reported at Rs 219.5 million as against Rs 244.7 million in Q4 FY21. However, Ebitda margin sustained at 22.3%.
Profit after tax reported at Rs 175 million as against Rs 211.2 million in Q4 FY21. Profit after tax margin reported at 17.8%.
Tatva Chintan's Earnings per share stood at Rs 7.90 as against Rs 10.51 in Q4 FY21 and Rs 10.29 in Q3 FY22.
The final dividend of Rs 2 per share is recommended by board of directors which is subject to the approval of shareholders.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.